Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Actemra, world's first drug for Castleman's disease launched in Japan

June 13, 2005

Protox receives funding to develop lung cancer drug

June 10, 2005

Virulizin granted orphan drug status in Europe

June 9, 2005

European orphan drug designation for Oncophage in renal cell carcinoma

June 9, 2005

Phase II trial for FavId in Europe

June 9, 2005

OncoVEX(GM-CSF) cleared for phase II study in malignant melanoma

June 9, 2005

HuMax-CD20 effective in killing tumor cells with low levels of CD20

June 7, 2005

DCVax-Brain cleared for phase II GBM trial

June 6, 2005

European orphan drug designation for Proxinium

June 6, 2005

COMP recommends orphan drug status for 1D09C3 for Hodgkin's lymphoma

June 3, 2005

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...